Literature DB >> 34331612

LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β-catenin/cyclin D1 signaling via PLAGL2.

Qinhua Liu1, Ruonan Ran2, Mingyue Song3, Xiaodan Li1, Zhengsheng Wu4, Guanrong Dai1, Ruixiang Xia5.   

Abstract

BACKGROUND: Although long non-coding RNA (lncRNA) HCP plays essential roles in human cancers, its function and mechanism in multiple myeloma (MM) have not crystallized.
METHODS: HCP5 level in MM was assessed through qRT-PCR. A series of functional investigations were conducted to evaluate the influences of HCP5 on proliferation and apoptosis. Bioinformatics analysis and RIP/RNA pull-down assays were carried out to determine the relationships among HCP5, miR-128-3p, and PLAGL2. Relative protein level was determined through Western blot. A xenograft tumor model was applied for validating the roles of HCP5/miR-128-3p/PLAGL2 axis in vivo.
RESULTS: HCP5 was significantly increased in MM. HCP5 knockdown effectively thwarted the proliferative rate and cell cycle of MM cell lines and suppressed tumor growth. HCP5 regulated PLAGL2 expression by sponging miR-128-3p. PLAGL2 overexpression effectively rescued cells from influences by sh-HCP5 on cell proliferative and apoptotic rates. Additionally, HCP5 knockdown significantly inhibited Wnt/β-catenin/cyclin D1 signaling, and these effects were eliminated by PLAGL2 overexpression.
CONCLUSION: Our study revealed that HCP5/miR-128-3p/PLAGL2 is closely correlated to MM development by modulating Wnt/β-catenin/cyclin D1 signaling. HCP5 promoted cell proliferation and tumor formation of MM cells by activating the Wnt/β-catenin/CCND1 signaling pathway by sponging miR-128-3p to increase PLAGL2 expression.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  HCP5; Multiple myeloma; PLAGL2; Tumorigenicity; miR-128-3p

Year:  2021        PMID: 34331612     DOI: 10.1007/s10565-021-09628-7

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  38 in total

1.  [Expression of Extracellular Matrix Protein Reelin in Patients with Multiple Myeloma and Its Relationship with Prognosis].

Authors:  Quan-Ming An; Yuan-Gen Liu; Liang Lin; Yang Liu; Jin Lu; Qing Ge
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2018-06

Review 2.  Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.

Authors:  Nicola Amodio; Patrizia D'Aquila; Giuseppe Passarino; Pierfrancesco Tassone; Dina Bellizzi
Journal:  Expert Opin Ther Targets       Date:  2017-01       Impact factor: 6.902

Review 3.  Targeting noncoding RNAs in disease.

Authors:  Brian D Adams; Christine Parsons; Lisa Walker; Wen Cai Zhang; Frank J Slack
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

4.  MiR-299-3p functions as a tumor suppressor in thyroid cancer by regulating SHOC2.

Authors:  X Chen; M Qi; Q Yang; J-Y Li
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-01       Impact factor: 3.507

5.  A role for IL-34 in osteolytic disease of multiple myeloma.

Authors:  Muhammad Baghdadi; Kozo Ishikawa; Sayaka Nakanishi; Tomoki Murata; Yui Umeyama; Takuto Kobayashi; Yosuke Kameda; Hiraku Endo; Haruka Wada; Bjarne Bogen; Satoshi Yamamoto; Keisuke Yamaguchi; Ikumi Kasahara; Hiroshi Iwasaki; Mutsumi Takahata; Makoto Ibata; Shuichiro Takahashi; Hideki Goto; Takanori Teshima; Ken-Ichiro Seino
Journal:  Blood Adv       Date:  2019-02-26

Review 6.  Advancements in Nanomedicine for Multiple Myeloma.

Authors:  Alexandre Detappe; Mark Bustoros; Tarek H Mouhieddine; P Peter Ghoroghchian
Journal:  Trends Mol Med       Date:  2018-05-17       Impact factor: 11.951

7.  Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

Authors:  Michele Cea; Antonia Cagnetta; Mariateresa Fulciniti; Yu-Tzu Tai; Teru Hideshima; Dharminder Chauhan; Aldo Roccaro; Antonio Sacco; Teresa Calimeri; Francesca Cottini; Jana Jakubikova; Sun-Young Kong; Franco Patrone; Alessio Nencioni; Marco Gobbi; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

8.  The lncRNA Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation.

Authors:  Ding-Wen Cao; Man-Man Liu; Rui Duan; Yi-Fu Tao; Jun-Shan Zhou; Wei-Rong Fang; Jun-Rong Zhu; Li Niu; Jian-Guo Sun
Journal:  Acta Pharmacol Sin       Date:  2019-08-20       Impact factor: 6.150

9.  SALL4 promotes the tumorigenicity of cervical cancer cells through activation of the Wnt/β-catenin pathway via CTNNB1.

Authors:  Mei Chen; Lu Li; Peng-Sheng Zheng
Journal:  Cancer Sci       Date:  2019-08-16       Impact factor: 6.716

10.  SYT1-associated neurodevelopmental disorder: a case series.

Authors:  Kate Baker; Sarah L Gordon; Holly Melland; Fabian Bumbak; Daniel J Scott; Tess J Jiang; David Owen; Bradley J Turner; Stewart G Boyd; Mari Rossi; Mohammed Al-Raqad; Orly Elpeleg; Dawn Peck; Grazia M S Mancini; Martina Wilke; Marcella Zollino; Giuseppe Marangi; Heike Weigand; Ingo Borggraefe; Tobias Haack; Zornitza Stark; Simon Sadedin; Tiong Yang Tan; Yunyun Jiang; Richard A Gibbs; Sara Ellingwood; Michelle Amaral; Whitley Kelley; Manju A Kurian; Michael A Cousin; F Lucy Raymond
Journal:  Brain       Date:  2018-09-01       Impact factor: 13.501

View more
  4 in total

Review 1.  LncRNA HCP5 as a potential therapeutic target and prognostic biomarker for various cancers: a meta‑analysis and bioinformatics analysis.

Authors:  Shao-Pu Hu; Meng-Xue Ge; Lei Gao; Min Jiang; Kai-Wen Hu
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

2.  FOXQ1-mediated SIRT1 upregulation enhances stemness and radio-resistance of colorectal cancer cells and restores intestinal microbiota function by promoting β-catenin nuclear translocation.

Authors:  Mei Yang; Qian Liu; Maolin Dai; Renqun Peng; Xinghui Li; Wei Zuo; Juhua Gou; Feixue Zhou; Shuangjiang Yu; Hao Liu; Min Huang
Journal:  J Exp Clin Cancer Res       Date:  2022-02-19

Review 3.  The Wnt/β-catenin signalling pathway in Haematological Neoplasms.

Authors:  Siwei Yu; Ruyue Han; Runliang Gan
Journal:  Biomark Res       Date:  2022-10-13

Review 4.  Long Noncoding RNAs: Recent Insights into Their Role in Male Infertility and Their Potential as Biomarkers and Therapeutic Targets.

Authors:  Shanjiang Zhao; Nuo Heng; Bahlibi Weldegebriall Sahlu; Huan Wang; Huabin Zhu
Journal:  Int J Mol Sci       Date:  2021-12-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.